X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7596) 7596
Book Chapter (14) 14
Dissertation (6) 6
Magazine Article (5) 5
Publication (4) 4
Book Review (2) 2
Conference Proceeding (2) 2
Reference (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ranibizumab (6398) 6398
ophthalmology (5247) 5247
humans (4873) 4873
male (3184) 3184
female (3156) 3156
bevacizumab (2957) 2957
macular degeneration (2784) 2784
aged (2700) 2700
intravitreal injections (2631) 2631
vascular endothelial growth factor a - antagonists & inhibitors (2300) 2300
middle aged (2100) 2100
angiogenesis inhibitors - therapeutic use (1928) 1928
vascular endothelial growth factor (1736) 1736
aged, 80 and over (1674) 1674
tomography, optical coherence (1641) 1641
treatment outcome (1555) 1555
angiogenesis inhibitors - administration & dosage (1422) 1422
retrospective studies (1414) 1414
visual acuity (1393) 1393
fluorescein angiography (1340) 1340
endothelial growth-factor (1269) 1269
visual acuity - physiology (1220) 1220
eye diseases (1215) 1215
follow-up studies (1145) 1145
age-related macular degeneration (1143) 1143
genetic structures (1097) 1097
macular degeneration - drug therapy (1083) 1083
diabetic retinopathy (1078) 1078
choroidal neovascularization (1027) 1027
choroidal neovascularization - drug therapy (962) 962
antibodies, monoclonal, humanized (912) 912
wet macular degeneration - drug therapy (912) 912
photodynamic therapy (894) 894
retina (863) 863
aflibercept (853) 853
optical coherence tomography (841) 841
prospective studies (835) 835
antibodies, monoclonal, humanized - therapeutic use (806) 806
therapy (805) 805
care and treatment (803) 803
macular edema - drug therapy (756) 756
edema (736) 736
sense organs (734) 734
verteporfin (677) 677
neovascularization (667) 667
injection (666) 666
adult (665) 665
diabetes (652) 652
physiological aspects (649) 649
age (644) 644
ranibizumab - therapeutic use (633) 633
patients (610) 610
ranibizumab - administration & dosage (597) 597
diabetic macular edema (574) 574
retinopathy (569) 569
macular edema (561) 561
antibodies, monoclonal, humanized - administration & dosage (559) 559
analysis (552) 552
diabetic retinopathy - drug therapy (536) 536
vegf (535) 535
anti-vegf (534) 534
eye (514) 514
angiogenesis inhibitors - adverse effects (513) 513
abridged index medicus (495) 495
intravitreal injection (486) 486
antibodies, monoclonal - therapeutic use (484) 484
intravitreal bevacizumab (481) 481
research (477) 477
medicine & public health (474) 474
safety (471) 471
drug therapy (458) 458
time factors (454) 454
injections (449) 449
wet macular degeneration - diagnosis (447) 447
antibodies, monoclonal - administration & dosage (438) 438
efficacy (435) 435
outcomes (430) 430
medical imaging (429) 429
prevalence (427) 427
animals (426) 426
intravitreal ranibizumab (420) 420
wet macular degeneration - physiopathology (418) 418
studies (413) 413
risk factors (400) 400
visual acuity - drug effects (399) 399
acuity (397) 397
choroidal neovascularization - etiology (397) 397
choroidal neovascularization - diagnosis (393) 393
angiogenesis (390) 390
pharmacology & pharmacy (382) 382
retina - pathology (376) 376
clinical trials (375) 375
fundus oculi (373) 373
endothelial growth factors (371) 371
recombinant fusion proteins - therapeutic use (369) 369
macular edema - etiology (364) 364
trial (354) 354
vitreous body (348) 348
visual-acuity (347) 347
receptors, vascular endothelial growth factor - therapeutic use (340) 340
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6850) 6850
German (312) 312
French (126) 126
Spanish (108) 108
Chinese (51) 51
Russian (49) 49
Turkish (39) 39
Czech (24) 24
Korean (22) 22
Japanese (20) 20
Polish (20) 20
Portuguese (20) 20
Hungarian (6) 6
Danish (4) 4
Swedish (4) 4
Italian (3) 3
Slovenian (3) 3
Hebrew (2) 2
Dutch (1) 1
Icelandic (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Journal Article
Journal Article
Retina, ISSN 0275-004X, 11/2017, Volume 37, Issue 11, pp. 2035 - 2046
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10011, pp. 2395 - 2403
Journal Article
BMJ Open, ISSN 2044-6055, 05/2019, Volume 9, Issue 5, p. e022031
Journal Article
Acta Ophthalmologica, ISSN 1755-375X, 05/2013, Volume 91, Issue 3, pp. e178 - e183
. Purpose:  Modern therapy of neovascular age‐related macular degeneration consists in intravitreal injections of inhibitors of the vascular endothelial growth... 
photodynamic therapy (Verteporfin®) | age‐related macular degeneration | Ranibizumab (Lucentis®) | choroidal neovascularization | vascular endothelial growth factor | Ranibizumab (Lucentis | photodynamic therapy (Verteporfin | age-related macular degeneration | INTRAVITREAL RANIBIZUMAB | photodynamic therapy (Verteporfin (R)) | DOSING REGIMEN | TRIAL | Ranibizumab (Lucentis (R)) | VERTEPORFIN PLUS RANIBIZUMAB | DISEASE | AMD | OPHTHALMOLOGY | SUBFOVEAL CHOROIDAL NEOVASCULARIZATION | Prospective Studies | Intravitreal Injections | Photosensitizing Agents - therapeutic use | Humans | Middle Aged | Male | Wet Macular Degeneration - physiopathology | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Photochemotherapy | Ranibizumab | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Microscopy, Acoustic | Visual Acuity - physiology | Fluorescein Angiography | Antibodies, Monoclonal, Humanized - therapeutic use | Porphyrins - therapeutic use | Tomography, Optical Coherence | Treatment Outcome | Combined Modality Therapy | Wet Macular Degeneration - diagnosis | Retreatment | Wet Macular Degeneration - drug therapy | Aged | Macular degeneration | Endothelial growth factors | Lasers in surgery | Physiological aspects | Ophthalmology | Neovascularization | Comparative analysis | Cancer | Drug therapy | Photodynamic therapy
Journal Article